Sagimet Biosciences Presents Two Posters At EASL 2026; Denifanstat/Resmetirom Phase 1 Data Selected As Best Of EASL, With Additional Preclinical Mechanism Findings Showcased
Sagimet Biosciences Inc SGMT
$7.04
▼ -3.16%
($-0.23)
Open
$7.23
Prev Close
$7.27
Day Range
$7.01 – $7.33
52W Range
$3.32 – $11.41
Market Cap
$444.81M
Beta
3.52
EPS (TTM)
$-1.34
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2023-07-14 |
| Shares Out. | 61,750,000 |
| Website | sagimet.com/ ↗ |
| Phone | 13026974590 |
Sagimet Biosciences Inc is a publicly traded company under the ticker symbol SGMT on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
18 analysts (2026-05-01)